Post-exposure prophylaxis for SIV revisited: Animal model for HIV prevention

被引：20

作者：

Emau P. ^{[1
]}

Jiang Y. ^{[1
]}

Agy M.B. ^{[1
]}

Tian B. ^{[1
]}

Bekele G. ^{[1
]}

Tsai C.-C. ^{[1
]}

机构：

[1] Washington National Primate Research Center, University of Washington, Seattle, WA 98195

来源：

AIDS Research and Therapy | / 3卷 / 1期

关键词：

Human Immunodeficiency Virus; Human Immunodeficiency Virus Prevention; Cynomolgus Macaque; Post Challenge; Plasma Viremia;

D O I：

10.1186/1742-6405-3-29

中图分类号：

学科分类号：

摘要：

Background: A 4-week, uninterrupted treatment with 9-(2-phosphonyl-methoxypropyly)adenine (PMPA, commonly called tenofovir) completely prevents simian immunodeficiency virus (SIVmne) infection in cynomolgus macaques if treatment begins within 24 hours after SIVmne inoculation, but is less effective if treatment is delayed or duration of treatment is shortened. Critical factors for efficacy include timing and duration of treatment, potency of antiretroviral drug and a contribution from antiviral immune responses. Therefore, we evaluated the impact of one or more treatment interruptions plus SIVmne reexposures on efficacy of PMPA treatment to prevent SIVmne infection in cynomolgus macaques. We also evaluated whether macaques with pre-existing SIV immune responses show increased efficacy of treatment. Eight PMPA-treated, virus-negative and seronegative macaques, and five PMPA-treated, virusnegative but weakly or strongly seropositive macaques were re-inoculated with SIVmne and treated with PMPA starting 24 hr post inoculation. Thereafter, they received either a 5-week treatment involving one interruption plus one SIVmne challenge or a 10-week treatment involving six interruptions plus six SIVmne challenges early during treatment. Parameters measured were plasma SIV RNA, SIV-antibody response, CD4+ T lymphocyte subsets and in vivo CD8+ cell-suppression of virus infection. Results: All seronegative macaques developed persistent antibody response beginning 4 to 8 weeks after stopping PMPA-treatment in absence of viremia in a majority of macaques and coinciding with onset of intermittent viremia in other macaques. In contrast, all weakly or strongly seropositive macaques showed immediate increase in titers (> 1600) of SIV antibodies, even before the end of PMPA-treatment, and in absence of detectable viremia. However, in vivo CD8+ -cell depletion revealed CD8 cell-suppression of viremia and persistence of virus in the macaques as long as 2 years after PMPA-treatment, even in aviremic macaques. Unlike untreated macaques, a treated macaque controlled viral replication and blocked CD4+ T cell depletion when challenged with a heterologus chimeric SIV/HIV-1 virus called SHIV89.6P. Conclusion: A single interruption plus one SIVmne challenge was as sufficient as six interruptions plus six SIVmne challenges in reducing efficacy of PMPA, but results in long-term persistence of virus infection suppressed by CD8+ cells. Efficacy of PMPA treatment was highest in macaques with pre-existing SIV immune responses. © 2006 Emau et al; licensee BioMed Central Ltd.

引用

共 41 条

[11] Bassett I.V., Freeberg K.A., Walensky R.P., Two drugs or three? Balancing efficacy, toxicity and resistance in post exposure prophylaxis for occupational exposure to HIV, Clin Infect Dis, 39, pp. 395-401, (2004)
[12] Gayle H.D., Expanding acess to HIV prevention, AIDS Res Ther, 3, (2006)
[13] Rosenberg E.S., Altfeld M., Poon S.H., Phillips M.N., Wilkes B.M., Eldridge R.L., Robbins G.K., D'Aquila R.T., Goulder P.J., Walker B.D., Immune control of HIV-1 after early treatment of acute infection, Nature, 407, pp. 523-526, (2000)
[14] Komarova N.L., Barnes E., Klenerman P., Wodarz D., Boosting immunity by antiviral drug therapy: A simple relationship among timing, efficacy and success, Proc Natl Acad Sci USA, 100, pp. 1855-1860, (2003)
[15] Tsai C.C., Emau P., Follis K.E., Beck W.T., Benveniste R.E., Bischofberger N., Lifson J.D., Morton W.R., Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIV mne infection depends critically on the timing of initiation and duration of treatment, J Virol, 72, pp. 4265-4273, (1998)
[16] Tsai C.C., Follis K.E., Sabo A., Beck W.T., Grant R.F., Bischofberger N., Benveniste R.E., Black R., Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)Adenine, Science, 270, pp. 1197-1199, (1995)
[17] Tsai C.C., Emau P., Sun J.C., Follis K.E., Beck W.T., Tran C.A., Bischofberger N., Morton W.R., Post-exposure chemoprophylaxis (PECP) against infection of macaques as a model for protection from HIV infection, J Med Primatol, 29, pp. 248-258, (2000)
[18] Lifson J.D., Rossio J.L., Piatak Jr. M., Parks T., Li L., Kiser R., Coalter V., Fisher B., Flynn B.M., Czajak S., Hirsch V.M., Reimann K.A., Schmidtz J.E., Ghrayeb J., Bischofberger N., Nowak M.A., Desrosiers R.C., Wodarz D., Role of CD8+ lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment, J Virol, 75, pp. 10187-10199, (2001)
[19] Kumar A., Buch S., Foresman L., Bischofberger N., Lifson J.D., Narayan O., Development of virus-specific immune responses in SHIV<sub>KU</sub>-infected macaques treated with PMPA, Virology, 279, pp. 97-108, (2001)
[20] Rosenwirth B., ten Haft P., Bogers W.M., Nieuwenhuis I.G., Niphuis H., Kuhn E.M., Bischofberger N., Heeney J.L., Uberla K., Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques, J Virol, 74, pp. 1704-1711, (2000)

← 1 2 3 4 5 →